Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin.
Alan F ListZhuoxin SunAmit K VermaJohn M BennettRami S KomrokjiKathy McGrawJaroslaw MaciejewskiJessica K AltmanPuneet S CheemaDavid F ClaxtonSelina M LugerRyan J MattisonTimothy R WassenaarAndrew S ArtzCharles A SchifferMark R LitzowMartin S TallmanPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
LEN restores sensitivity to recombinant erythropoietin in growth factor-insensitive, lower-risk, non-del(5q) MDS, to yield a significantly higher rate and duration of MER compared with LEN alone (funded by the National Cancer Institute; E2905 ClinicalTrials.gov identifier: NCT02048813).